Popularly known for its ability to enhance facial appearance cosmetically, Botox is now under scrutiny for its possible application for treating major depressive disorder, based on data from a study undertaken by Allergan. Read More »
The paper "Radioimmunotherapy for Acute Myeloid Leukemia Targeting Human Aspartyl (Asparaginyl) β-Hydroxylase” was presented at the American Association for Cancer Research (AACR) meeting by Panacea Pharmaceuticals on April 3. Read More »
Teaming up to enhance North Carolina’s public health outcomes, Purdue Pharma of Stamford, Connecticut; nationwide Project Lazarus; and Safe Kids North Carolina recently entered a three-way collaboration via the North Carolina Disposal Initiative (NCDI). Read More »
To treat some of Huntington disease’s harshest symptoms and help restore quality of life to those suffering from the rare, fatal neurodegenerative disease, the U.S. Food and Drug Administration recently approved a medication created by Teva Pharmaceutical Industries. Read More »
Health care supply distributor McKesson Corp. of San Francisco has completed its acquisition of CoverMyMeds LLC, an Ohio-based source of electronic authorization technology for medical providers and pharmacists. Read More »
Change Healthcare recently announced the unveiling of InterQual 2017, the company’s flagship clinical decision support solution. Read More »
Amgen and UCB recently announced that their phase 2 study for Evenity (romosozumab) showed positive fourth-year results for efficacy and safety as a second course of treatment for postmenopausal women with osteoporosis. Read More »
Bristol-Myers Squibb Co. and Incyte Corp. have agreed to advance their clinical development program. Read More »
Amgen recently announced that the company submitted to the U.S. Food and Drug Administration (FDA) a supplemental Biologics License Application (sBLA) for Xgeva (denosumab). The company also seeks approval from the European Medicines Agency (EMA). Read More »
The European Medicines Agency has accepted a Marketing Authorization Application for brexpiprazole, and its review is anticipated in the second quarter of 2018. Read More »
Acorda Therapeutics Inc. recently announced that the United States District Court for the District of Delaware invalidated four of its patents related to Ampyra extended release tablets. Read More »
Incyte Corp. and Merck have initiated a clinical development program that will examine the possibility of combining epacadostat, Incyte’s investigational oral selective IDO1 enzyme inhibitor, with Keytruda (pembrolizumab), Merck’s anti-PD-1 therapy, in patients with metastatic melanoma, non-small cell lung cancer (NSCLC), bladder cancer, renal cell carcinoma (RCC), and squamous cell carcinoma of the head and neck (SCCHN). Read More »
Mylan N.V. has acquired the global rights to Cold-EEZE, a cold remedy line of products, from ProPhase Labs Inc. Read More »
Allergy & Asthma Network and Avella Specialty Pharmacy have released a white paper underscoring latex allergy risks and how that relates to the health care industry. Read More »
Mylan N.V. recently released a brief statement regarding the status of its Abbreviated New Drug Application for its generic iteration of GlaxoSmithKline's Advair Diskus bronchodilator product. Read More »
AbbVie has received approval from the U.S. Food and Drug Administration to include moderate to severe fingernail psoriasis data in the Humira (adalimumab) prescribing information for patients with moderate to severe chronic plaque psoriasis. Read More »
Senators pushing for changes to Medicare Part D drug pricing reporting requirements should be wary of messing with the program, according to a former administrator of the Centers for Medicare and Medicaid Services. Read More »
In an effort to obtain legitimate protections for seniors, taxpayers and pharmacies, pharmaceutical wholesaler Smith Drug Company recently expressed support for Congressional legislation to prevent benefit managers from billing customers retroactively for Medicare Part D prescriptions. Read More »
The U.S. Food and Drug Administration’s Oncologic Drugs Advisory Committee voted 11-0 on a favorable benefit-risk ratio for Genentech's rituximab/hyaluronidase subcutaneous injections in treating certain blood cancers. Read More »
Amgen's esults from its Phase 2, open-label ALCANTARA study evaluating the efficacy and safety of BLINCYTO has been published in the Journal of Clinical Oncology. Read More »
Alerts Sign-up
